10-Q: LENSAR Inc. Reports Q3 2024 Results: Revenue Up 38% Year-Over-Year

LENSAR Inc. saw a significant revenue increase in Q3 2024, driven by strong product sales and procedure volume growth.

Summary

• LENSAR Inc. reported a 38% increase in total revenue for the third quarter of 2024, reaching $13.5 million, compared to $9.8 million in the same period of 2023.
• Product revenue increased by 48% to $10.6 million, primarily due to higher ALLY System sales and increased procedure volume.
• Lease revenue rose by 13% to $1.7 million, while service revenue increased by 11% to $1.2 million.
• The company's net loss for the quarter was $1.5 million, compared to a net profit of $2.6 million in Q3 2023.
• For the nine months ended September 30, 2024, total revenue increased by 22% to $36.8 million, compared to $30.1 million in the same period of 2023.
• The net loss for the nine-month period was $12.7 million, which included a $3.7 million impairment charge on intangible assets, compared to a net loss of $10.5 million in the same period of 2023.
• The company's installed base of systems is approximately 355 as of September 30, 2024.

Sentiment

Score: 6

Explanation: The document presents a mixed picture. While there is strong revenue growth, the company is still operating at a loss and faces significant risks. The positive revenue growth is offset by the net loss and the potential need for future capital raises. The sentiment is cautiously optimistic, but with a clear awareness of the challenges ahead.

Positives

• The company experienced a significant increase in product revenue, driven by ALLY System sales and procedure volume.
• Lease and service revenue also showed growth, indicating a strong demand for the company's offerings.
• The company is expanding its international presence with regulatory clearances in the EU and Taiwan.

Negatives

• The company reported a net loss of $1.5 million in Q3 2024, compared to a net profit in the same period last year.
• The net loss for the nine-month period was $12.7 million, which included a $3.7 million impairment charge on intangible assets.
• The company is experiencing inflationary pressures and supply chain disruptions, which may impact future profitability.

Risks

• The company faces risks related to economic uncertainty, which could impact revenue and profitability.
• The company's growth depends on obtaining additional regulatory clearances and certifications for the ALLY System.
• Patients may not be willing to pay the price difference for advanced cataract procedures using the company's laser systems.
• The company faces competition from larger companies with more established products and greater resources.
• The company is exposed to credit risk from customers, which could result in material losses.
• The company may be unable to accurately forecast customer demand and inventory levels.
• The company is subject to extensive government regulation and oversight, and failure to comply could harm the business.
• The company is subject to risks related to intellectual property and other intellectual property matters.
• The company is subject to cybersecurity risks that could disrupt operations and negatively impact the business.

Future Outlook

The company expects annual revenue and selling, general and administrative expenses to increase from current levels associated with the increase in ALLY System placements. The company's liquidity needs will be largely determined by its ability to continue to successfully commercialize its products and the progression, additional regulatory clearances or certifications and launch of the ALLY System in additional jurisdictions in the future. The company may need to raise additional capital through equity or debt financings, borrowings under credit facilities or from other sources in the future.

Management Comments

• Management believes the Companys cash and cash equivalents on hand, together with cash generated from the future sale and lease of products, will provide sufficient funds for its operating, investing, and financing cash flows for a period of at least twelve months from the date of issuance of these financial statements.
• The Companys growth depends in part on the Companys ability to produce the ALLY System in sufficient quantities, within requested timelines and at an acceptable price to satisfy customer demand.

Industry Context

The medical device market, particularly in ophthalmology, is highly competitive and technology-driven. LENSAR's focus on advanced laser systems for cataract treatment positions it within a growing segment of the market, but it faces competition from larger, more established companies. The company's ability to innovate and gain regulatory approvals will be crucial for its success.

Comparison to Industry Standards

• LENSAR's revenue growth of 38% in Q3 2024 is strong compared to the average growth rates of other medical device companies in the ophthalmology sector, which typically range from 5% to 15% annually.
• Companies like Alcon and Johnson & Johnson, which are major players in the ophthalmic surgical market, have more established products and greater resources, making LENSAR's growth more impressive.
• The company's focus on robotic laser cataract surgery with the ALLY System is a differentiating factor, as many competitors still rely on traditional methods or older laser technologies.
• However, LENSAR's net loss indicates that it is still in a growth phase and needs to achieve profitability, which is a common challenge for smaller medical device companies.
• Compared to other companies in the medical device industry, LENSAR's reliance on a network of international distributors is a common practice, but it also exposes the company to risks associated with third-party performance and international business operations.

Corporate Governance

Legal Proceedings

• Stockholders Ryan Schaper and Christopher P. Bolster filed a Verified Amended Class Action Complaint against the Company and certain of its officers and members of the board of directors, alleging violations of Sections 14(a) and 20(a) of the Exchange Act, as well as Rule 14d-9 promulgated thereunder, and asserting claims challenging the adequacy of disclosures in the definitive proxy statement filed with the SEC on June 20, 2023, in connection with the Private Placement.
• The company vigorously denies that the definitive proxy statement filed with the SEC on June 20, 2023 was deficient in any respect, or that that supplemental disclosures were required or necessary under applicable laws.

Related Party Transactions

• In June 2023, the Company entered into an international distribution agreement in India with a company owned by an employee at that time. The related party relationship ended on April 1, 2024.

Stakeholder Impact

• Shareholders may experience dilution if the company raises additional capital through equity offerings.
• Employees may benefit from the company's growth and expansion, but may also face challenges related to increased workload and competition for talent.
• Customers may benefit from the company's innovative products, but may also face higher costs for advanced cataract procedures.
• Suppliers may benefit from increased demand for components, but may also face pressure to meet the company's quality and delivery requirements.
• Creditors may be exposed to increased risk if the company's financial performance deteriorates.

Next Steps

• The company will continue to focus on the commercialization of the ALLY System.
• The company will pursue additional regulatory clearances and certifications for the ALLY System in new markets.
• The company will continue to expand its sales and marketing efforts in the U.S. and internationally.

Key Dates

Keywords

ALLY System, cataract surgery, laser system, medical device, revenue growth, regulatory clearance, ophthalmology, procedure volume, financial results, LENSAR